PainReform's Strategic Progress: A Mid-Year Business Review
PainReform's Mid-Year Business Update
TEL AVIV, Israel — PainReform Ltd. (NASDAQ: PRFX), a specialty pharmaceutical company focused on innovative therapeutics and energy technologies, shares its business developments for the first half of 2025.
Highlighting Key Achievements
Key Highlights:
- Acquired a majority stake in LayerBio, introducing OcuRing™-K, a dropless therapy targeting a significant global market.
- Progressed R&D on PRF-110, revealing promising efficacy in managing postoperative pain.
- Expanded DeepSolar with a Smart Energy Management app and secured a commercial agreement following a successful pilot.
- Reduced net loss significantly to $2.3M compared to last year's $12.8M, sustaining a strong cash position.
Pharmaceutical Innovations Transforming Pain Management
Ehud Geller, Chairman and interim CEO, emphasized the transformational nature of the first half of 2025 for PainReform. The acquisition of LayerBio and its pioneering OcuRing™-K platform is a strategic advancement. This innovation aims to mitigate pain and inflammation in patients post-cataract surgery, standing as a non-opioid alternative in the global market valued at approximately $9 billion. With promising developments in PRF-110, PainReform is actively broadening its portfolio of non-opioid solutions to address significant clinical demands.
Expanding the DeepSolar Initiative
PainReform's DeepSolar division is gaining momentum, showcasing various advancements. The launch of the MyDeepSolar consumer app allows users to optimize solar efficiency through cutting-edge AI analytics. Additionally, the acceptance into NVIDIA's Connect Program marks a pivotal step in the development of DeepSolar Predict, enhancing solar forecasting capabilities. Following a successful 92MW pilot project with Econergy, PainReform is transitioning DeepSolar into its first commercial phase, paving the way for greater market reach.
Financial Performance Overview
For the first half of 2025, research and development expenses significantly decreased to approximately $0.3 million, compared to $11.4 million during the same period in 2024. This drop follows the conclusion of a Phase 3 clinical trial for PRF-110.
Moreover, general and administrative expenses rose to about $1.9 million from $1.5 million year-over-year, attributed to higher legal and compensation costs. Financial income was recorded at roughly $52,000, a decline from $92,000 in 2024, largely due to reduced cash balances.
Looking Ahead: Sustainable Growth Strategies
As of June 30, 2025, PainReform's cash and cash equivalents totaled $3.5 million, supported by positive working capital of $1.5 million. The company aims to balance growth opportunities with financial prudence, reducing operating expenses and optimizing resources for sustained value creation across its pharmaceutical and energy sectors.
Understanding the Business Model
PainReform's dual business model integrates pharmaceutical advancements and energy optimization technologies. The company’s innovative drug-delivery systems promise prolonged pain relief, reducing the burdens associated with traditional opioid use. Meanwhile, DeepSolar’s adoption of AI-driven solutions enhances energy management and monitoring, reinforcing PainReform's commitment to sustainability.
Contact Information
For further information, please reach out to:
Crescendo Communications, LLC
Tel: 212-671-1021
Email: prfx@crescendo-ir.com
Dr. Ehud Geller
Chairman and interim Chief Executive Officer
PainReform Ltd.
Tel: +972-54-4236711
Email: egeller@medicavp.com
Frequently Asked Questions
What recent achievements did PainReform announce?
PainReform highlighted significant advancements, including the acquisition of LayerBio and the development of non-opioid therapies.
How is PainReform performing financially?
The company reported a net loss of $2.3M for the first half of 2025, substantially lower than the prior year.
What is the focus of PainReform's pharmaceutical division?
The pharmaceutical division focuses on developing non-opioid therapeutic solutions, particularly for postoperative pain management.
What is the DeepSolar initiative about?
DeepSolar aims to provide AI-driven solar energy solutions, enhancing efficiency and forecasting for users and businesses.
How can one contact PainReform for more information?
Interested parties can contact Crescendo Communications or Dr. Ehud Geller for inquiries.
About The Author
Contact Caleb Price privately here. Or send an email with ATTN: Caleb Price as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
